Market by Product and Service, Type, Application, Technology, Industry Vertical, and Country Outlook | Forecast 2024-2032
As per Triton Market Research’s report estimates, the Europe multiplex assay market is set to attain revenue growth at a compound annual growth rate of 8.17% over the forecasting period 2024-2032.
Report scope can be customized per your requirements - Request Free Sample Report
The countries assessed in this region are:
• United Kingdom
• Germany
• France
• Italy
• Spain
• Netherlands
• Rest of Europe
The steady growth of the multiplex assay market in Europe is expected due to several factors. These include the European Government’s emphasis on technological progress in medical devices, robust healthcare systems, and the upward trend in healthcare expenditure. Additionally, the market is fueled by the rising incidence of chronic diseases and the aging population in Europe.
Germany leads the market with the majority of shares. One key factor supporting the market’s growth is the rising incidence of new cancer cases. The Centre for Cancer Registry Data consistently evaluates and studies the yearly influx of new cancer cases in Germany using data sourced from federal state cancer registries. This escalating prevalence is driving the advancement of new therapies. As a result, the drug development process and clinical trials are increasingly embracing multiplex assays.
Similarly, the growth in demand can be attributed significantly to the rising incidence of cancer cases in the United Kingdom. Recent figures from Cancer Research UK indicate approximately 375,000 new cases annually, averaging around 1,000 cases daily. Among these, females contribute a substantial portion of the yearly cases, while males make up the remainder. The heightened prevalence of cancer has thus spurred a greater need for multiplex assays, which are extensively utilized in cancer research and diagnostics.
The protein microarray is a sophisticated method that enables the simultaneous monitoring of multiple proteins to understand their activities, functions, and interactions. Its applications span diagnostics, protein functional analysis, proteomics, antibody characterization, and the discovery of new drugs for treating diseases. For example, Thermo Fisher Scientific provides an advanced protein microarray called ProtoArray, which facilitates tasks like identifying biomarkers and studying protein-protein interactions.
The market is sectioned based on technology, industry vertical, application, type, and product and service. The technology section includes multiplex protein microarray, multiplex PCR, and other technologies.
The renowned companies in the market are Abcam Limited, Becton Dickinson and Company, Agilent Technologies Inc, Bio-Rad Laboratories Inc, and Bio-Techne Corporation.
Abcam Limited is a provider of protein research tools, offering a wide array of antibodies, inhibitors, proteins, peptides, activators, lysates, biochemicals, and imaging tools for cell and tissue studies. Additionally, it supplies immunoassay kits and reagents. Abcam primarily caters to academic researchers seeking protein solutions for life sciences. The company has manufacturing facilities and offices across multiple countries, including Japan and the US. Established in 1998, Abcam is headquartered in Cambridge, UK.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the multiplex assay market revenue growth in Europe and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the Europe multiplex assay market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
MULTIPLEX ASSAY MARKET- SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
ANALYSIS ON THE MULTIPLEX ASSAY MARKET
2.1.1. IMPACT
OF COVID-19 ON THE MULTIPLEX ASSAY MARKET
2.2. PORTER’S
FIVE FORCES MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTE PRODUCTS
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. COMPETITIVE
RIVALRY
2.3. KEY
BUYING IMPACT ANALYSIS
2.3.1. ANALYTE
COVERAGE
2.3.2. SPEED
2.3.3. MULTIPLEXING
CAPABILITY
2.3.4. EASE
OF USE
2.3.5. AUTOMATION
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. KEY
MARKET STRATEGIES
2.5.1. CONTRACTS
AND PARTNERSHIPS
2.5.2. BUSINESS
EXPANSIONS & DIVESTITURES
2.5.3. ACQUISITIONS
& MERGERS
2.5.4. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6. MARKET
DRIVERS
2.6.1. ADOPTION
OF PERSONALIZED MEDICINES
2.6.2. HIGH
ADOPTION OF MULTIPLEX ASSAYS OVER TRADITIONAL METHODS
2.6.3. INCREASING
PREVALENCE OF CHRONIC DISEASES
2.7. MARKET
CHALLENGES
2.7.1. ISSUES
RELATED TO CROSS-REACTIVITY AND ASSAY INTERFERENCE
2.7.2. CHALLENGE
IN ACHIEVING ADEQUATE ASSAY RANGE
2.7.3. DEARTH
OF SKILLED PROFESSIONALS
2.8. MARKET
OPPORTUNITIES
2.8.1. TECHNOLOGICAL
ADVANCEMENTS IN ASSAY PLATFORMS
2.8.2. RAPID
GROWTH OF COMPANION DIAGNOSTICS
2.8.3. GROWTH
IN DRUG DISCOVERY INITIATIVES
2.9. ANALYST
PERSPECTIVE
3. EUROPE
MULTIPLEX ASSAY MARKET - BY PRODUCT AND SERVICE
3.1. REAGENTS
AND CONSUMABLES
3.2. INSTRUMENTS
AND ACCESSORIES
3.3. SOFTWARE
AND SERVICES
4. EUROPE
MULTIPLEX ASSAY MARKET - BY TYPE
4.1. PROTEIN-BASED
MULTIPLEX ASSAY
4.2. NUCLEIC
ACID-BASED MULTIPLEX ASSAY
4.3. OTHER
MULTIPLEX ASSAYS
5. EUROPE
MULTIPLEX ASSAY MARKET - BY APPLICATION
5.1. RESEARCH
AND DEVELOPMENT
5.2. CLINICAL
DIAGNOSTICS
5.3. COMPANION
DIAGNOSTICS
6. EUROPE
MULTIPLEX ASSAY MARKET - BY TECHNOLOGY
6.1. MULTIPLEX
PROTEIN MICROARRAY
6.2. MULTIPLEX
PCR
6.3. OTHER
TECHNOLOGIES
7. EUROPE
MULTIPLEX ASSAY MARKET - BY INDUSTRY VERTICAL
7.1. PHARMACEUTICAL
& BIOTECHNOLOGY COMPANIES
7.2. RESEARCH
INSTITUTES
7.3. CLINICAL
LABORATORIES
7.4. HOSPITALS
8. EUROPE
MULTIPLEX ASSAY MARKET – BY COUNTRY OUTLOOK
8.1. GERMANY
8.1.1. GERMANY
MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
8.2. UNITED
KINGDOM
8.2.1. UNITED
KINGDOM MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
8.3. FRANCE
8.3.1. FRANCE
MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
8.4. ITALY
8.4.1. ITALY
MARKET FORECAST & PROSPECTS
8.5. SPAIN
8.5.1. SPAIN
MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
8.6. NETHERLANDS
8.6.1. NETHERLANDS
MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
8.7. REST
OF EUROPE
8.7.1. REST
OF EUROPE MULTIPLEX ASSAY MARKET FORECAST & PROSPECTS
9. COMPETITIVE
LANDSCAPE
9.1. ABCAM
LIMITED
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.2. AGILENT
TECHNOLOGIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY CHALLENGES
9.3. BECTON
DICKINSON AND COMPANY (BD)
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. BIO-RAD
LABORATORIES INC
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. BIO-TECHNE
CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.6. F.
HOFFMANN-LA ROCHE LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY STRENGTHS
9.6.4. KEY CHALLENGES
9.7. ILLUMINA
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY STRENGTHS
9.7.4. KEY CHALLENGES
9.8. MERCK
MILLIPORE
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.9. OLINK
PROTEOMICS AB
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.10. QIAGEN
NV
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY STRENGTHS
9.10.4. KEY CHALLENGES
9.11. RANDOX
LABORATORIES LTD
9.11.1. OVERVIEW
9.11.2. PRODUCT
PORTFOLIO
9.12. SEEGENE
INC
9.12.1. OVERVIEW
9.12.2. PRODUCT
PORTFOLIO
9.13. SIEMENS
HEALTHINEERS AG
9.13.1. OVERVIEW
9.13.2. PRODUCT
PORTFOLIO
9.13.3. KEY
STRENGTHS
9.13.4. KEY
CHALLENGES
9.14. THERMO
FISHER SCIENTIFIC INC
9.14.1. OVERVIEW
9.14.2. PRODUCT
PORTFOLIO
9.14.3. KEY
STRENGTHS
9.14.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE
1: EUROPE MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, HISTORICAL YEARS,
2020-2023 (IN $ MILLION)
TABLE
2: EUROPE MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, FORECAST YEARS, 2024-2032
(IN $ MILLION)
TABLE
3: CONTRACTS AND PARTNERSHIPS
TABLE
4: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE
5: ACQUISITIONS & MERGERS
TABLE
6: LIST OF NEW PRODUCT LAUNCHES & DEVELOPMENTS
TABLE
7: EUROPE MULTIPLEX ASSAY MARKET, BY PRODUCT AND SERVICE, 2024-2032 (IN $
MILLION)
TABLE
8: EUROPE MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2032 (IN $ MILLION)
TABLE
9: EUROPE MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2032 (IN $ MILLION)
TABLE
10: EUROPE MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2032 (IN $ MILLION)
TABLE
11: EUROPE MULTIPLEX ASSAY MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $
MILLION)
TABLE
12: EUROPE MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
FIGURE
1: EUROPE MULTIPLEX ASSAY MARKET, BY PRODUCT AND SERVICE, 2023 & 2032 (IN %)
FIGURE
2: EUROPE MULTIPLEX ASSAY MARKET, BY REAGENTS AND CONSUMABLES, 2024-2032 (IN $
MILLION)
FIGURE
3: EUROPE MULTIPLEX ASSAY MARKET, BY INSTRUMENTS AND ACCESSORIES, 2024-2032 (IN
$ MILLION)
FIGURE
4: EUROPE MULTIPLEX ASSAY MARKET, BY SOFTWARE AND SERVICES, 2024-2032 (IN $
MILLION)
FIGURE
5: EUROPE MULTIPLEX ASSAY MARKET, BY TYPE, 2023 & 2032 (IN %)
FIGURE
6: EUROPE MULTIPLEX ASSAY MARKET, BY PROTEIN-BASED MULTIPLEX ASSAY, 2024-2032
(IN $ MILLION)
FIGURE
7: EUROPE MULTIPLEX ASSAY MARKET, BY NUCLEIC ACID-BASED MULTIPLEX ASSAY,
2024-2032 (IN $ MILLION)
FIGURE
8: EUROPE MULTIPLEX ASSAY MARKET, BY OTHER MULTIPLEX ASSAYS, 2024-2032 (IN $
MILLION)
FIGURE
9: EUROPE MULTIPLEX ASSAY MARKET, BY APPLICATION, 2023 & 2032 (IN %)
FIGURE
10: EUROPE MULTIPLEX ASSAY MARKET, BY RESEARCH AND DEVELOPMENT, 2024-2032 (IN $
MILLION)
FIGURE
11: EUROPE MULTIPLEX ASSAY MARKET, BY CLINICAL DIAGNOSTICS, 2024-2032 (IN $
MILLION)
FIGURE
12: EUROPE MULTIPLEX ASSAY MARKET, BY COMPANION DIAGNOSTICS, 2024-2032 (IN $
MILLION)
FIGURE
13: EUROPE MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2023 & 2032 (IN %)
FIGURE
14: EUROPE MULTIPLEX ASSAY MARKET, BY MULTIPLEX PROTEIN MICROARRAY, 2024-2032
(IN $ MILLION)
FIGURE
15: EUROPE MULTIPLEX ASSAY MARKET, BY MULTIPLEX PCR, 2024-2032 (IN $ MILLION)
FIGURE
16: EUROPE MULTIPLEX ASSAY MARKET, BY OTHER TECHNOLOGIES, 2024-2032 (IN $
MILLION)
FIGURE
17: EUROPE MULTIPLEX ASSAY MARKET, BY INDUSTRY VERTICALS, 2023 & 2032 (IN %)
FIGURE
18: EUROPE MULTIPLEX ASSAY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY
COMPANIES, 2024-2032 (IN $ MILLION)
FIGURE
19: EUROPE MULTIPLEX ASSAY MARKET, BY RESEARCH INSTITUTES, 2024-2032 (IN $
MILLION)
FIGURE
20: EUROPE MULTIPLEX ASSAY MARKET, BY CLINICAL LABORATORIES, 2024-2032 (IN $
MILLION)
FIGURE
21: EUROPE MULTIPLEX ASSAY MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE
22: EUROPE MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE
23: GERMANY MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
24: UNITED KINGDOM MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
25: FRANCE MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
26: ITALY MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
27: SPAIN MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
28: NETHERLANDS MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
29: REST OF EUROPE MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)